tiprankstipranks
Advertisement
Advertisement

KROS Stock Latest News

Keros Therapeutics Earns Milestone Payment for Elritercept Trial
Company AnnouncementsKeros Therapeutics Earns Milestone Payment for Elritercept Trial
2d ago
8K
KROS
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
PremiumThe Fly
Keros Therapeutics to receive $20M elritercept milestone payment from Takeda
2d ago
TAK
KROS
Keros Therapeutics Announces CFO Resignation and Interim Successor
PremiumCompany Announcements
Keros Therapeutics Announces CFO Resignation and Interim Successor
10d ago
8K
KROS
Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors
PremiumCompany Announcements
Keros Therapeutics’ TROPOS Trial Termination: What It Means for KROS Investors
30d ago
KROS
Keros Therapeutics Appoints Anne Prener to Board
PremiumCompany Announcements
Keros Therapeutics Appoints Anne Prener to Board
1M ago
8K
KROS
Keros Therapeutics Stockholders Approve Directors and Governance Matters
PremiumCompany AnnouncementsKeros Therapeutics Stockholders Approve Directors and Governance Matters
2M ago
8K
KROS
Keros Therapeutics CEO to Present at Goldman Sachs Conference
Premium
Company Announcements
Keros Therapeutics CEO to Present at Goldman Sachs Conference
2M ago
8K
KROS
Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
Premium
Ratings
Hold Rating Reiterated on Keros as Takeda Partnership Progress Offsets Rinvatercept Delays; $16 Price Target Maintained
2M ago
KROS
Keros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target
PremiumRatings
Keros Therapeutics: Buy Rating Reaffirmed on Rinvatercept-Focused Strategy and Unchanged $20 Price Target
3M ago
KROS
Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)
PremiumThe Fly
Keros Therapeutics reports Q1 EPS ($1.21), consensus (92c)
3M ago
KROS
Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks
PremiumRatings
Balanced Hold on Keros as Rinvatercept Progress Offsets Execution and Timeline Risks
5M ago
KROS
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
PremiumCompany Announcements
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
5M ago
8K
KROS
Keros Therapeutics announces collaboration with Sean M. Healey & AMG Center
PremiumThe FlyKeros Therapeutics announces collaboration with Sean M. Healey & AMG Center
5M ago
KROS
Keros Therapeutics presents additional data from Phase 1 of rinvatercept
Premium
The Fly
Keros Therapeutics presents additional data from Phase 1 of rinvatercept
5M ago
KROS
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility
Premium
Company Announcements
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility
5M ago
KROS
Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo
PremiumThe Fly
Keros Therapeutics price target lowered to $20 from $23 at Wells Fargo
5M ago
KROS
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
PremiumCompany Announcements
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
5M ago
8K
KROS
KROS Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
KROS Upcoming Earnings Report: What to Expect?
5M ago
KROS
Keros Therapeutics Adds Veteran Finance Leader to Board
PremiumCompany Announcements
Keros Therapeutics Adds Veteran Finance Leader to Board
5M ago
8K
KROS
Keros Therapeutics CEO to Present at Multiple Conferences
PremiumCompany AnnouncementsKeros Therapeutics CEO to Present at Multiple Conferences
5M ago
8K
KROS
Keros Therapeutics Highlights Rinvatercept Strategy in Updated Presentation
Premium
Company Announcements
Keros Therapeutics Highlights Rinvatercept Strategy in Updated Presentation
7M ago
8K
KROS
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
8M ago
NNE
ABTC

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >